NLRP3 Inflammasome May Be a Biomarker for Risk Stratification in Patients with Acute Coronary Syndrome

References

• Hedayati T, Yadav N, Khanagavi J. Non-ST-segment acute coronary syndromes. Cardiol Clin. 2018;36(1):37–52. doi:10.1016/j.ccl.2017.08.003
   PubMed Web of Science ®Google Scholar
• Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. doi:10.1016/j.jacc.2017.04.052
   PubMed Web of Science ®Google Scholar
• Mehta SR, Wood DA, Storey RF, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019;381(15):1411–1421. doi:10.1056/NEJMoa1907775
   PubMed Web of Science ®Google Scholar
• Buccheri S, Franchina G, Romano S, et al. Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography–Guided Percutaneous Coronary Intervention With Stent Implantation. JACC Cardiovasc Interv. 2017;10(24):2488–2498. doi:10.1016/j.jcin.2017.08.051
   PubMed Web of Science ®Google Scholar
• de Carvalho LP, Gao F, Chen Q, et al. Long-term prognosis and risk heterogeneity of heart failure complicating acute myocardial infarction. Am J Cardiol. 2015;115(7):872–878. doi:10.1016/j.amjcard.2015.01.010
   PubMed Web of Science ®Google Scholar
• Quan X-Q, Wang R-C, Zhang Q, Zhang C-T, Sun L. The predictive value of lymphocyte-to-monocyte ratio in the prognosis of acute coronary syndrome patients: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2020;20(1):338. doi:10.1186/s12872-020-01614-x
   PubMed Web of Science ®Google Scholar
• Afari ME, Bhat T. Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update. Expert Rev Cardiovasc Ther. 2016;14(5):573–577. doi:10.1586/14779072.2016.1154788
   PubMed Web of Science ®Google Scholar
• Wang L, Cong H-L, Zhang J-X, et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):80. doi:10.1186/s12933-020-01054-z
   PubMed Web of Science ®Google Scholar
• Westman PC, Lipinski MJ, Luger D, et al. Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. J Am Coll Cardiol. 2016;67(17):2050–2060. doi:10.1016/j.jacc.2016.01.073
   PubMed Web of Science ®Google Scholar
• Ruparelia N, Godec J, Lee R, Chai JT. Acute myocardial infarction activates distinct inflammation and proliferation pathways in circulating monocytes, prior to recruitment, and identified through conserved transcriptional responses in mice and humans. Eur Heart J. 2015;36(29):1923–1934. doi:10.1093/eurheartj/ehv195
   PubMed Web of Science ®Google Scholar
• Zhang WJ, Chen SJ, Zhou SC, Wu SZ, Wang H. Inflammasomes and Fibrosis. Front Immunol. 2021;12:643149. doi:10.3389/fimmu.2021.643149
   PubMed Web of Science ®Google Scholar
• Haneklaus M, O’Neill LAJ. NLRP3 at the interface of metabolism and inflammation. Immunol Rev. 2015;265(1):53–62. doi:10.1111/imr.12285
   PubMed Web of Science ®Google Scholar
• Toldo S, Mauro AG, Cutter Z, et al. The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse. J Cardiovasc Pharmacol. 2019;73(4):215–222. doi:10.1097/FJC.0000000000000658
   PubMed Web of Science ®Google Scholar
• Yang F, Qin Y, Wang Y, et al. Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. Int J Biol Sci. 2019;15(5):1010–1019. doi:10.7150/ijbs.29680
   PubMed Web of Science ®Google Scholar
• Feng H, Mou SQ, Li WJ, et al. Resveratrol Inhibits Ischemia-Induced Myocardial Senescence Signals and NLRP3 Inflammasome Activation. Oxid Med Cell Longev. 2020;2020:2647807. doi:10.1155/2020/2647807
   PubMed Web of Science ®Google Scholar
• Afrasyab A, Qu P, Zhao Y, et al. Correlation of NLRP3 with severity and prognosis of coronary atherosclerosis in acute coronary syndrome patients. Heart Vessels. 2016;31(8):1218–1229. doi:10.1007/s00380-015-0723-8
   PubMed Web of Science ®Google Scholar
• Peng H, Wu H, Zhang G, et al. Expression and Clinical Prognostic Value of Platelet NLRP3 in Acute Coronary Syndrome. Int J Gen Med. 2020;13:791–802. doi:10.2147/IJGM.S275481
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–e1143. doi:10.1161/CIR.0000000000000625
   PubMed Web of Science ®Google Scholar
• Puymirat E, Bonaca M, Fumery M, et al. Atherothrombotic risk stratification after acute myocardial infarction: the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. Clin Cardiol. 2019;42(2):227–234. doi:10.1002/clc.23131
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–2264. doi:10.1016/j.jacc.2018.08.1038
   PubMed Web of Science ®Google Scholar
• Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144(22):e368–e454.
   Web of Science ®Google Scholar
• Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019;139(11):1384–1395. doi:10.1161/CIRCULATIONAHA.118.037778
   PubMed Web of Science ®Google Scholar
• Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. 2018;15(4):203–214. doi:10.1038/nrcardio.2017.161
   PubMed Web of Science ®Google Scholar
• Couchie D, Vaisman B, Abderrazak A, et al. Human Plasma Thioredoxin-80 Increases With Age and in ApoE −/− Mice Induces Inflammation, Angiogenesis, and Atherosclerosis. Circulation. 2017;136(5):464–475. doi:10.1161/CIRCULATIONAHA.117.027612
   PubMed Web of Science ®Google Scholar
• Lliberos C, Liew SH, Zareie P, La Gruta NL, Mansell A, Hutt K. Evaluation of inflammation and follicle depletion during ovarian ageing in mice. Sci Rep. 2021;11(1):278. doi:10.1038/s41598-020-79488-4
   PubMed Web of Science ®Google Scholar
• Toldo S, Mezzaroma E, McGeough MD, et al. Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. Cardiovasc Res. 2015;105(2):203–212. doi:10.1093/cvr/cvu259
   PubMed Web of Science ®Google Scholar
• Shen S, Wang Z, Sun H, Ma L. Role of NLRP3 Inflammasome in Myocardial Ischemia-Reperfusion Injury and Ventricular Remodeling. Med Sci Monit. 2022;28:e934255. doi:10.12659/MSM.934255
   PubMed Web of Science ®Google Scholar
• Sethwala AM, Goh I, Amerena JV. Combating Inflammation in Cardiovascular Disease. Heart Lung Circ. 2021;30(2):197–206. doi:10.1016/j.hlc.2020.09.003
   PubMed Web of Science ®Google Scholar
• Bian F, Yang X-Y, Xu G, Zheng T, Jin S. CRP-Induced NLRP3 Inflammasome Activation Increases LDL Transcytosis Across Endothelial Cells. Front Pharmacol. 2019;10:40. doi:10.3389/fphar.2019.00040
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang S, Liu J, et al. D-dimer and the incidence of heart failure and mortality after acute myocardial infarction. Heart. 2021;107(3):237–244. doi:10.1136/heartjnl-2020-316880
   PubMed Web of Science ®Google Scholar
• Chen R, Liu C, Zhou P, et al. Prognostic Value of D-dimer in patients with acute coronary syndrome treated by percutaneous coronary intervention: a retrospective cohort study. Thromb J. 2021;19(1):30. doi:10.1186/s12959-021-00281-y
   PubMed Web of Science ®Google Scholar
• Koch V, Booz C, Gruenewald LD, et al. Diagnostic performance and predictive value of D-dimer testing in patients referred to the emergency department for suspected myocardial infarction. Clin Biochem. 2022;104:22–29. doi:10.1016/j.clinbiochem.2022.02.003
   PubMed Web of Science ®Google Scholar
• Maloberti A, Biolcati M, Ruzzenenti G, et al. The Role of Uric Acid in Acute and Chronic Coronary Syndromes. J Clin Med. 2021;10(20):20. doi:10.3390/jcm10204750
   Web of Science ®Google Scholar
• Rebora P, Centola M, Morici N, et al. Uric acid associated with acute heart failure presentation in Acute Coronary Syndrome patients. Eur J Intern Med. 2022;99:30–37. doi:10.1016/j.ejim.2022.01.018
   PubMed Web of Science ®Google Scholar
• Gao R, Shi H, Chang S, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. Int Immunopharmacol. 2019;74:105575. doi:10.1016/j.intimp.2019.04.022
   PubMed Web of Science ®Google Scholar
• Zhao M, Zhang J, Xu Y, et al. Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation. Int Immunopharmacol. 2021;99:108046. doi:10.1016/j.intimp.2021.108046
   PubMed Web of Science ®Google Scholar
• Aliaga J, Bonaventura A, Mezzaroma E, et al. Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177® (Dapansutrile) in a Mouse Model of Severe Ischemic Cardiomyopathy Due to Non-Reperfused Anterior Wall Myocardial Infarction. Molecules. 2021;26(12):12. doi:10.3390/molecules26123534
   Web of Science ®Google Scholar
• Nie C, Zou R, Pan S. Hydrogen gas inhalation ameliorates cardiac remodelling and fibrosis by regulating NLRP3 inflammasome in myocardial infarction rats. J Cell Mol Med. 2021;25(18):8997–9010. doi:10.1111/jcmm.16863
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao D, Feng J, et al. LuQi Formula Regulates NLRP3 Inflammasome to Relieve Myocardial-Infarction-Induced Cardiac Remodeling in Mice. Evid Based Complement Alternat Med. 2021;2021:5518083. doi:10.1155/2021/5518083
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838–1847. doi:10.1056/NEJMoa2021372
   PubMed Web of Science ®Google Scholar
• Silvis MJM, Fiolet ATL, Opstal TSJ, et al. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: a LoDoCo2 biomarker substudy. Atherosclerosis. 2021;334:93–100. doi:10.1016/j.atherosclerosis.2021.08.005
   PubMed Web of Science ®Google Scholar
• Deftereos SG, Beerkens FJ, Shah B, et al. Colchicine in Cardiovascular Disease: in-Depth Review. Circulation. 2022;145(1):61–78. doi:10.1161/CIRCULATIONAHA.121.056171
   PubMed Web of Science ®Google Scholar
• Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42(28):2765–2775. doi:10.1093/eurheartj/ehab115
   PubMed Web of Science ®Google Scholar
• Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394–1400. doi:10.1016/j.amjcard.2013.01.287
   PubMed Web of Science ®Google Scholar
• Abbate A, Trankle CR, Buckley LF, et al. Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment–Elevation Myocardial Infarction. J Am Heart Assoc. 2020;9(5):e014941. doi:10.1161/JAHA.119.014941
   PubMed Web of Science ®Google Scholar
• Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39(38):3499–3507. doi:10.1093/eurheartj/ehy310
   PubMed Web of Science ®Google Scholar
• Toldo S, Mauro AG, Cutter Z, Abbate A. Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2018;315(6):H1553–H1568. doi:10.1152/ajpheart.00158.2018
   PubMed Web of Science ®Google Scholar
• Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020;126(9):1260–1280. doi:10.1161/CIRCRESAHA.120.315937
   PubMed Web of Science ®Google Scholar
• Busch K, Kny M, Huang N, et al. Inhibition of the NLRP3/IL-1β axis protects against sepsis-induced cardiomyopathy. J Cachexia Sarcopenia Muscle. 2021;12(6):1653–1668. doi:10.1002/jcsm.12763
   PubMed Web of Science ®Google Scholar